Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

BACKGROUND: Patient-derived xenograft (PDX) tumor model has become a new approach in identifying druggable tumor mutations, screening and evaluating personalized cancer drugs based on the mutated targets. METHODS: We established five nasopharyngeal carcinoma (NPC) PDXs in mouse model. Subsequently,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Cheng-Lung, Lui, Kar-Wai, Chi, Lang-Ming, Kuo, Yung-Chia, Chao, Yin-Kai, Yeh, Chun-Nan, Lee, Li-Yu, Huang, Yenlin, Lin, Tung-Liang, Huang, Mei-Yuan, Lai, Yi-Ru, Yeh, Yuan-Ming, Fan, Hsien-Chi, Lin, An-Chi, Lu, Yen-Jung, Hsieh, Chia-Hsun, Chang, Kai-Ping, Tsang, Ngan-Ming, Wang, Hung-Ming, Chang, Alex Y., Chang, Yu-Sun, Li, Hsin-Pai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149192/
https://www.ncbi.nlm.nih.gov/pubmed/30236142
http://dx.doi.org/10.1186/s13046-018-0873-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149192/
https://www.ncbi.nlm.nih.gov/pubmed/30236142
http://dx.doi.org/10.1186/s13046-018-0873-5

Ejemplares similares